Mood Disorder Questionnaire (MDQ)

The Mood Disorder Questionnaire (MDQ) is a 15-item self-report screening instrument that can be used to identify clients most likely to have bipolar disorder. The MDQ assists in identifying bipolar disorder and distinguishing it from other mood disturbances in clinical populations.

Past research has found that MDQ total scores are associated with anxiety, trauma-related, substance use, eating, and impulse control disorders, in addition to BD (Paterniti & Bisserbe, 2018; Zimmerman et al., 2011). As a result, there have been two subscales identified (Carpenter et al., 2020):

• Positive Activation: increased energy/activity, grandiosity, and decreased need for sleep. This subscale is specific to BD.
• Negative Activation: irritability, racing thoughts, levels of negative affectivity, and distractibility. This subscale is more broadly related to emotion dysregulation and transdiagnostic personality traits.

Research indicates that effective treatment of bipolar disorder (BD) differs significantly from that of other related disorders, such as unipolar depression (Carpenter et al., 2020). This underscores the importance of screening for bipolar disorder (BD) in patients who present to mental health services so that they can receive an effective intervention. For example, the use of antidepressants in BD treatment is controversial (Sidor & MacQueen, 2011) and psychotherapy treatment more often involves addressing issues such as unrealistic goal-setting and impulsivity in patients with BD than in others (Geddes & Miklowitz, 2013; Miklowitz & Johnson, 2006). As BD is associated robustly with significant psychosocial impairment (e.g., poor work and relationship functioning), failing to detect cases of BD can lead to suboptimal treatment approaches and, thereby, exacerbate personal and societal costs associated with BD (Conus, Macneil, & McGorry, 2014).  

Psychometric Properties

The internal reliability for the MDQ is strong (Cronbach’s alpha = 0.88; Stanton & Watson, 2017).

Traditionally, a positive screen on the MDQ requires endorsement of (a) 7 or more of 13 symptom items, (b) multiple symptoms occurring at the same time, and (c) symptoms causing notable psychosocial impairment (Hirschfeld et al., 2000). The first thirteen questions on the MDQ are based upon bipolar symptoms and a score of 7 or more is the optimal cutoff, as it provides good sensitivity (73%) and very good specificity for a diagnosis of BD (90%; Hirschfeld et al., 2000). However, results from a number of studies suggest that the MDQ is not unidimensional (Ruggero et al., 2014; Stanton & Watson, 2017).

Carpenter et al. (2020) and Stanton and Watson (2017) investigated the structure of the MDQ’s 13 symptom items and found that the MDQ was best represented by two factors, which they termed Positive Activation (e.g., “had much more energy”; “was much more confident”) and Negative Activation (e.g., “thoughts raced”; “felt very irritable”) symptom dimensions. Three of the MDQ symptoms (items 5, 10, and 11) loaded highly onto both Positive and Negative Activation factors and were removed from the final model. Carpenter et al. (2020) found that Positive Activation was uniquely associated with BD diagnosis, whereas Negative Activation was associated with a range of diagnoses. Thus, a 4-item Positive Activation subscale (α = .82) and a 6-item Negative Activation subscale (α = .73) was created.  

Scoring and Interpretation 

A total score is calculated for questions 1-13 where a “Yes” provides a score of 1 and “No” is 0. The percentage of items endorsed (raw score / number of items multiplied by 100) is included to provide an indication of the proportion of symptoms identified with by the respondent.

In order to meet the threshold for bipolar disorder the traditional scoring method is as follows:

• A score of 7 or more for questions 1-13 (53% of items endorsed) AND
• Check “yes” for the item asking if the symptoms clustered in the same time period (question 14) AND
• Symptoms caused either “moderate” or “serious” problems (question 15).

Subscale scores were also developed (Carpenter et al., 2020, Stanton & Watson, 2017) using 10 of the 13 items in the symptom questions:

• Positive Activation (items 3, 4, 8, 9): assesses increased energy/activity, grandiosity, and decreased need for sleep. Individuals endorsing symptoms defining Positive Activation are not likely to report significant levels of negative affect and are likely to be energetic and extraverted. Individuals scoring high on Positive Activation may be less likely to rate their symptoms as impairing given that increased levels of energy and activity may be experienced as advantageous to some degree, especially if they are mild in nature. This factor is strongly associated with a BD diagnosis.
• Negative Activation (items 1, 2, 6, 7, 12, 13): assesses irritability, racing thoughts, levels of negative affectivity, and distractibility. This factor is strongly associated with BD as well as a a range of other disorders, many of them (e.g. depressive disorders, PDs, PTSD, GAD, substance use disorders) characterised by emotion dysregulation and/or transdiagnostic personality traits such as neuroticism and disinhibition. Clients high in Negative Activation may be at risk for engaging in impulsive behavior in emotional situations.

Clinical percentiles are also presented for the two subscales as developed by Carpenter et al. (2020) on over 1,700 outpatients (for a variety of diagnoses). A percentile of 50 means that the client has scored at the average level compared with the clinical group for that subscale.  

Developer

Hirschfeld, R. M., Williams, J. B., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Jr, Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., Russell, J. M., Sachs, G. S., & Zajecka, J. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. The American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873  

References

Carpenter, R. W., Stanton, K., Emery, N. N., & Zimmerman, M. (2020). Positive and Negative Activation in the Mood Disorder Questionnaire: Associations With Psychopathology and Emotion Dysregulation in a Clinical Sample. Assessment, 27(2), 219–231. https://doi.org/10.1177/1073191119851574

Hirschfeld, R. M., Williams, J. B., Spitzer, R. L., Calabrese, J. R., Flynn, L., Keck, P. E., Jr, Lewis, L., McElroy, S. L., Post, R. M., Rapport, D. J., Russell, J. M., Sachs, G. S., & Zajecka, J. (2000). Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. The American Journal of Psychiatry, 157(11), 1873–1875. https://doi.org/10.1176/appi.ajp.157.11.1873 

Stanton, K., & Watson, D. (2017). Explicating the structure and relations of the Mood Disorder Questionnaire: Implications for screening for bipolar and related disorders. Journal of Affective Disorders, 220, 72–78. https://doi.org/10.1016/j.jad.2017.05.046